Nutrition Research and Practice, 7 (4), 249255
Weight loss is known to trigger compensatory biology: Increased appetite signaling Reduced resting energy expenditure Heightened food reward sensitivity Stopping GLP-1 therapy at peak dose, without tapering and without reinforcing lifestyle strategies at the exact moment hunger returns, does not allow lifestyle behaviors to take over. Emerging real-world data and obesity physiology suggest a different, more clinically relevant path: Gradual dose reduction rather than abrupt cessation Continued, structured dietary and exercise support Active monitoring during the high-risk post-cessation period We still need randomized trials designed specifically to test tapering and lifestyle-anchored maintenance strategies
however, they function differently and may be better suited to meet distinct needs
Switching between GLP-1 treatments, such as from Wegovy to Mounjaro, is possible and can be discussed during your consultation
In ogni caso, la distinzione fondamentale: una compressa GLP-1 non equivale automaticamente a una pillola per dimagrire
